Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C3H5O3.Na |
Molecular Weight | 112.0598 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].C[C@H](O)C([O-])=O
InChI
InChIKey=NGSFWBMYFKHRBD-DKWTVANSSA-M
InChI=1S/C3H6O3.Na/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);/q;+1/p-1/t2-;/m0./s1
Molecular Formula | C3H5O3 |
Molecular Weight | 89.07 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Lactic Acid, L- (L-lactic acid, L-lactate) is the levorotatory isomer of lactic acid, the biologically active isoform in humans. Lactic acid or lactate is produced during fermentation from pyruvate by lactate dehydrogenase. Lactate dehydrogenase is isomer-specific so that production and metabolism of D-lactate require D-LDH and L-lactate requires L-LDH. Mammalian cells only contain L-LDH so that in humans the lactate produced is almost exclusively L-lactate. Carbohydrate-fermenting bacterial species (e.g. lactobacillus spp) have by contrast both enzymes and therefore the capacity to produce both D-lactate and L-lactate. L-lactic acid is the primary agonist of hydroxycarboxylic acid receptor 1 (HCA1), which is a Gi/o-coupled G protein-coupled receptor (GPCR). Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to restore volume and stimulate collagen formation gradually. It is FDA-approved for the correction of facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people for the correction of nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck, thighs, gluteal enhancement and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9BXC0 Gene ID: 27198.0 Gene Symbol: HCAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21454438 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PRISMASOL Approved UsePRISMASOL solution is indicated as a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances. Launch Date1.16164801E12 |
PubMed
Title | Date | PubMed |
---|---|---|
High resolution 1H n.m.r. studies of vertebrate blood and plasma. | 1983 Jun 1 |
|
Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls. | 1988 Feb |
|
Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate. | 1991 May |
|
Standardized method for high-resolution 1H-NMR of cerebrospinal fluid. | 1995 May |
|
Asymmetric intramolecular [2 + 2] photocycloadditions: alpha- and beta-hydroxy acids as chiral tether groups. | 2002 Feb 22 |
|
Asymmetric total synthesis of (+)-brefeldin A from (S)-lactate by triple chirality transfer process and nitrile oxide cycloaddition. | 2002 Feb 8 |
|
1H and (13)C NMR spectroscopic analysis of human saliva. | 2002 Jun |
|
Synthesis of optically active atropisomeric anilide derivatives through diastereoselective N-allylation with a chiral Pd-pi-allyl catalyst. | 2003 Dec 12 |
|
Structure of the O-polysaccharide of Proteus penneri 28 and Proteus vulgaris O31 and classification of P. penneri 26 and 28 in Proteus serogroup O31. | 2003 Oct 24 |
|
Asymmetric intermolecular C-H functionalization of benzyl silyl ethers mediated by chiral auxiliary-based aryldiazoacetates and chiral dirhodium catalysts. | 2005 Dec 23 |
|
Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition. | 2005 May 9 |
|
Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise. | 2006 Jan |
|
Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder. | 2007 Jan 15 |
|
Facile alcoholysis of L-lactide catalysed by Group 1 and 2 metal complexes. | 2008 Jun 21 |
|
An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. | 2010 Apr 7 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/poly-l-lactic-acid.html
Facial fat loss (lipoatrophy) Sculptra (Poly-L-lactic acid): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by ≥2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:08 UTC 2023
by
admin
on
Fri Dec 15 15:13:08 UTC 2023
|
Record UNII |
P2Y1C6M9PS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29730
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB36522
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
867-56-1
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
DTXSID5052830
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
P2Y1C6M9PS
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
C61944
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
100000128870
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
23664767
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
P2Y1C6M9PS
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY | |||
|
212-762-3
Created by
admin on Fri Dec 15 15:13:08 UTC 2023 , Edited by admin on Fri Dec 15 15:13:08 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|